Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

491.67 -0.80 (-0.16%)
Streaming Delayed Price Updated: 2:59 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
53 54 Next >
Magnificent 7 Lose Over $300B As Volatility Index Surges, Traders Question Fed's Timing: What's Driving Markets Friday?
Wall Street is experiencing a sharp decline on the last trading day of the week, with all indices in the red at noon in New York, as a cooler-than-expected July jobs report rattled risk sentiment and... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline
Vertex Pharmaceuticals reported Q2 revenues of $2.65B, near the $2.66B estimate, with an adjusted EPS loss of $(12.83), missing the $4.14 consensus. The analyst expects strong growth in the pain... 
Via Benzinga
Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second.
Vertex's first loss in years is a big nothingburger. 
Via The Motley Fool
Vertex Pharmaceuticals (VRTX) Q2 2024 Earnings Call Transcript
VRTX earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Vertex Slumps On Light Second-Quarter Despite Hiked 2024 Outlook
The company's sales came in a hair light with losses wider than expected. 
Via Investor's Business Daily
14 Analysts Assess Vertex Pharmaceuticals: What You Need To Know
Via Benzinga
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting. 
Via Benzinga
Topics Economy
Exposures Interest Rates
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market... 
Via Benzinga
Got $500? 2 Compelling Growth Stocks to Buy and Hold Forever
These businesses are looking like increasingly attractive buys. 
Via The Motley Fool
Why VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) qualifies as a quality stock.
Is VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) suited for quality investing? 
Via Chartmill
Forecasting The Future: 13 Analyst Projections For Vertex Pharmaceuticals
Via Benzinga
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a... 
Via Benzinga
The Top 3 Biotech Stocks to Buy Now Summer 2024
These biotech stocks are well-positioned to generate high returns for investors due to their significant growth prospects. 
Via InvestorPlace
DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?
DexCom faces several challenges, but GLP-1 drugs aren't big problems for the company right now. 
Via The Motley Fool
The Top 3 Cathie Wood Stocks to Buy Now: Summer 2024
The investing guru likes to take the pulse of where the world will be tomorrow and these Cathie Wood stocks reflect that vision. 
Via InvestorPlace
2 No-Brainer Growth Stocks to Buy With $1,000 Right Now
These companies are paving the way to future growth and market share in their respective industries. 
Via The Motley Fool
Is Vertex Pharmaceuticals' Monopoly in Danger?
As a shareholder, I am nowhere close to panic mode. 
Via The Motley Fool
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Vertex shares have soared by triple-digit percentages over the past three years. 
Via The Motley Fool
7 Biotech Stocks to Keep on Your Clinical Radar
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
Via InvestorPlace
Here's How Much $100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today
Via Benzinga
3 Gene Editing Stocks Shaping the Future of Medicine
Gene editing stocks offer a bold venture into biopharma's future, leveraging CRISPR technology for transformative healthcare solutions 
Via InvestorPlace
2 Historically Flawless Metrics Suggest the Stock Market Can Plunge: Here Are 3 Stocks I've Sold Ahead of What May Be a Big Move for Wall Street
Neither of these predictive indicators has ever been wrong when back-tested for more than 150 years! 
Via The Motley Fool
3 Monster Stocks in the Making to Buy Right Now
They're small now, but these stocks could grow much larger. 
Via The Motley Fool
The 3 Best Neuroscience Biotech Stocks to Buy Now
Given the high bar to developing good neuroscience drugs, firms that do so will likely succeed. Here are three top biotech stocks to buy now. 
Via InvestorPlace
Looking for growth without the hefty price tag? Consider NASDAQ:VRTX.
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) is not too expensive for the growth it is showing. 
Via Chartmill
3 Gene Editing Stocks That Could Grow Your Wealth
Investors looking for gene editing stocks of cutting edge technology firms should consider these biotech stocks. 
Via InvestorPlace
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
CRISPR Therapeutics could start reporting product revenue soon. 
Via The Motley Fool
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
These innovative drugmakers are hard to ignore. 
Via The Motley Fool
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Revenue is climbing at these two drug companies -- and the trend should continue. 
Via The Motley Fool
Got $1,000? 2 Incredible Growth Stocks to Buy and Hold Forever
These companies have what it takes to stand the test of time in a portfolio. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.